Trials / Conditions / Stage III Lip and Oral Cavity Cancer AJCC v8

Stage III Lip and Oral Cavity Cancer AJCC v8

16 registered clinical trials studyying Stage III Lip and Oral Cavity Cancer AJCC v8 — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cann NCT07441681	NRG Oncology	Phase 3
Recruiting	Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Ca NCT07195734	National Cancer Institute (NCI)	Phase 2
Recruiting	Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN281 NCT06980038	National Cancer Institute (NCI)	Phase 2
Not Yet Recruiting	Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squ NCT07156227	National Cancer Institute (NCI)	Phase 1
Recruiting	Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Sq NCT07121595	University of Michigan Rogel Cancer Center	Phase 2
Recruiting	Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy f NCT06532279	NRG Oncology	Phase 2
Terminated	A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade NCT05316688	University of Washington	Phase 1 / Phase 2
Withdrawn	Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carbopl NCT06084845	ECOG-ACRIN Cancer Research Group	Phase 2
Recruiting	BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Mel NCT05136196	National Cancer Institute (NCI)	Phase 2
Withdrawn	A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Canc NCT05512767	Mayo Clinic	N/A
Recruiting	Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer NCT05172245	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Tr NCT04576091	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cance NCT04533750	National Cancer Institute (NCI)	Phase 1
Completed	Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With NCT04541355	Hyunseok Kang, MD	Phase 2
Completed	Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck NCT03258554	National Cancer Institute (NCI)	Phase 2 / Phase 3
Recruiting	Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of NCT02734537	ECOG-ACRIN Cancer Research Group	Phase 2